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COST ANALYSIS OF HOME-BASED MEDICATION REVIEWS IN A MULTI-ETHNIC
ASIAN POPULATION: A PILOT STUDY
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1National University of Singapore, Singapore, Singapore, 2Frontier Healthcare Group, Singapore,
Singapore, 3Singapore General Hospital, Outram, Singapore, 4Guardian Pharmacy, Singapore,
Singapore
OBJECTIVES: To evaluate the feasibility and cost of conducting home-based med-
ication reviews (HBMR) among community-dwelling multi-ethnic Singaporeans
and permanent residents.METHODS: In this cross-sectional study, Chinese, Malay
and Indian aged 40 and over and on at least 5 medications were referred by their
general practitioners (GPs) for HBMR. Patients completed a survey on sociodemo-
graphic and clinical information. Pharmacists’ time spent on HBMR and preparing
visit reports were captured and assigned a cost based on pharmacists’ average
hourly wages. Drug related problems (DRP) were evaluated using the Westerlund
DRP classification system, reported to and followed up with the GPs. RESULTS: Of
14 participants referred, 9 consented (64.3%; 6 women; 6 Chinese, 2 Malays, 1 In-
dian; mean (SD, range) age: 69.3 (10.6, 52 – 86 years). Seven out of the 9 patient were
under the care of at least two physicians. Dyslipidemia, hypertension and diabetes
are themain condition affecting the participants (100%, 88.9%, 66.7%, respectively).
A total of 12 DRP were detected: underuse of medication (n7, of which 2 were due
to non-compliance), overuse of medication (n1), incorrect timing (n2) and ther-
apy failure (n2). Pharmacists spent an average 3.5 hours per home visit. Total
programme cost was $787.5 (9 visits x $25/hr x 3.5hr/ visit). Hence, cost per DRP
detected was estimated at $65.63. One of the DRP detected was vertigo without
treatment. Hence, programme cost may be potentially offset by the savings from
avoiding an episode of hospitalization due to fall. CONCLUSIONS: DRP is prevalent
and potentially preventable but were undetected in this primary care sample.
Hence, there is a role for HBMR. We are currently conducting a longitudinal ran-
domized controlled trial to evaluate the cost-effectiveness of providing and not
providing HBMR by collecting direct and indirect costs, health services utilization
and health-related quality of life outcomes at baseline and 6-months.
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FACTORS MAY INFLUENCE PATTERN OF MEDICINE’S USE
Soleymani F1, Ahmadizar F2, Abdollahi M1, Meysami A1
1Tehran University of Medical Sciences, Tehran, Iran, 2Ministry of Health, Tehran, Iran
OBJECTIVES: Pharmacists have a remarkable role in rational use of drug by presen-
tation of drug information as patient educator, explanation, assessment and per-
formance of drug orders, contribution in drug selection and utilization as physician
consultant, drug utilization review and participation in patient outcomes in am-
bulatory settings.The aim of this study is to evaluate pharmacists’ opinion about
the factors affecting rational drug use. METHODS: In a cross sectional survey,
questionnaires of the study were completed in Convenient Sampling by pharma-
cists who had been attended in rational use of drug congress in Tehran. RESULTS:
A total of 147 pharmacists were enrolled to the study and the highest priorities in
irrational use of drug by pharmacists were revealed including 39% lack of appro-
priate cooperation and communication between physicians and pharmacists, 34%
pharmacists’ low tariff and economic issues, 45% lack of public knowledge about
drug use and 15.8% lack of regulations. CONCLUSIONS: Lack of public knowledge
and awareness about appropriate use of medicines was found the most important
factor in promoting irrationality in drug use. Dissemination of rational use of drug
ideas, compiling of diverse strategies in education, management, regulation and
finance can be very efficient due to a strong relationship between drug policies and
performance of regulations and supervisions as well as drug services methods.
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A 3-YEAR FOLLOW-UP STUDY ON NATIONAL HEALTH INSURANCE
REIMBURSEMENTS AMONG ATRIAL FIBRILLATION PATIENTS WITH/WITHOUT
STROKE IN TAIWAN: A POPULATION-BASED STUDY
Liu CY1, Chen HC1, Chen SA2
1National Taipei University of Nursing and Health Sciences, Taipei City, Taiwan, Taiwan, 2Taipei
Veterans General Hospital, Taipei City, Taiwan, Taiwan
OBJECTIVES: To evaluate the 3-year National Health Insurance reimbursements
among atrial fibrillation (AF) patients with and without stroke in one year in
Taiwan.METHODS: The data were retrieved from the Taiwan Longitudinal Health
Insurance Database, which consists 1,000,000 Taiwanese people’s claimed data
from 2005 to 2008. The study cohort consisted of 17,427 patients with newly diag-
nosed AF in 2005 and 537 occurred stroke in 2006. Each patient was individually
followed-up for 3 years period from 2006 to 2008. The generalized linear model
(GLZM) was used to estimate the health care reimbursements and the risk to hos-
pitalize among AF patients. RESULTS: The estimated incidence rate of atrial fibril-
lation was 1.74% per person year. Besides, among AF patients, the estimated inci-
dence of stroke was 3.08% per person year. After adjusting for age and sex, AF
patients with stroke had statistically significant higher outpatient reimbursement
(NTD$44, 941 vs 38,078/person-year) and inpatient reimbursement (NTD$ 1,630,222
vs. 960,702/person-year) than AF patients without stroke. Also, the results of GLZM
revealed a statistically significant hazard ratio to be hospitalized in AF patients
with stroke (HR1.93; 95% CI1.73-2.15, p-value0.001). AF patients with stroke,
however, did not have statistically significant difference of annual outpatient visits
from AF patients without stroke (33 vs 32 times/person-year). CONCLUSIONS: This
study demonstrated that AF patients with strokewere found to utilize significantly
more national health insurance reimbursements than AF-alone patients and also
to be at a significant higher risk of hospitalization during a 3-year follow-up period
after diagnosis.
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MAKING MONEY WORK FOR IMPROVEMENT OF PATIENT CARE: SUCCESS AND
SHORTCOMINGS OF PAY-FOR-PERFORMANCE PROGRAM IN TAIWAN
Chawla A, Rana C, Bhutani MK, Gupta J
Heron Health Pvt. Ltd., Chandigarh, India
OBJECTIVES: Pay-for-Performance (P4P) programwas introduced in Taiwan in 2001
for treatment of breast cancer (BC), diabetes mellitus (DM), tuberculosis (TB),
asthma, and cervical cancer. Although P4P is increasingly being implemented,
there remains insufficient evidence to support the belief that the P4P incentive
design improved the outcomes of care.METHODS: Embase® and MEDLINE® were
searched from 2001-2012 using the key terms pay-for-performance and P4P for
studies published in English. RESULTS: Of the 1413 screened, 14 studies assessing
P4P program in Taiwan were identified. Studies assessing P4P in patients with
asthma and cervical cancerwere not retrieved. The BC-P4P enrolees received better
quality care (p0.001), resulting in better 5-year overall survival (odds ratio [OR]:
5.99; p0.003) and less recurrence (OR: 2.70; p0.002) when compared to non-
enrolees. The effect was more pronounced in low-volume hospitals (OR: 1.38;
[95%CI: 1.08 - 1.77]) and non-medical centres (OR: 1.62; [95%CI: 1.24 - 2.11]). Among
TB-P4P enrolees, cure rate within 12 months of treatment significantly increased
(OR, 1.338; [95%CI: 1.159 - 1.544]), whereas default rate from treatment significantly
decreased (OR, 0.904; [95%CI: 0.702 - 0.973]) compared to non-P4P enrolees. In DM-
P4P enrolees, the cost of diabetes-related physician visits was higher (5731 NT$/
patient), however, costs of diabetes-related hospitalisations (-5099 NT$/patient)
and overall expenditures on health services (-10 543 NT$/patient) were consider-
ably lower compared to non-enrolees. Hospitals in cities with low-income levels
were more likely to participate in P4P programs compared to hospitals in high-
income level cities (OR: 4.53; [95%CI: 2.87 - 7.16]). The results illustrated that older
patients and patients with high co-morbidity/severity were prone to be excluded
from P4P programs. CONCLUSIONS: Patients enrolled in the P4P program received
a better quality of care and demonstrated better outcomes than the non-enrolled
patients. However, benefit of P4P can be extended by including older patients and
those with higher disease severity and co-morbidities.
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SUBMISSION OF NEW DRUG REIMBURSEMENT AND PRICING APPLICATIONS TO
NATIONAL HEALTH INSURANCE (NHI) OF TAIWAN, MEETING OUTCOMES OF
THE DRUG BENEFIT COMMITTEE
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OBJECTIVES: The Drug Benefit Committee (DBC) appraises the value of new drug
and categorises it as class 1 (substantial improvement), 2A (moderate improve-
ment) or 2B (similar) according to relative treatment effect of new drug compared
with the exiting treatment(s), and pricing method link to the category is decided.
When DBC considers more information is required the application will be further
discussed in extension meeting, and appeal could be entered if the license holder
did not agree upon the result. We analyzed the features of new drug applications
and corresponding DBCmeeting outcomes in 2007 and 2008.METHODS:Data were
abstracted from the applications and DBC meeting minute. RESULTS: There were
82 applications during the study period, 51 were submitted by the multinational
companies and 31 by domestic companies; 6 applied for class 1; and 70were single-
compound. By end of 2008, 63 (77%) were reimbursed; for the unreimbursed, 7 were
withdrawn by the applicants and 12were denied by theDBC. 20 newdrugs received
unconditional recommendation, 43 with conditional coverage. 31 (38%) submis-
sions entered appeals, 22 for price and 9 for reimbursement decision. Appealed
successfully in 22 (71%), but double the duration to reach final result. The final
reimbursed prices were 81% to 91% of the applied price in class 1, and 55% to 73% in
class 2. The feature of company (foreign or domestic) and the ratio of applied to the
first DBC decided price had influence on the decision of company to enter an
appeal. CONCLUSIONS: The reimbursement and price process is evolving contin-
uously. How to justify the value of treatment to the community, scientific sound
methods for assessment and appraisal, and transparency of the process and out-
comes are the important considerations. The cumulative experience is valuable for
future improvement.
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EVIDENCE REQUIREMENTS FOR PRICING AND REIMBURSEMENT DECISION
MAKING FOR ORPHAN DRUGS IN ASIA
Tan S1, Dummett H2, Kirpekar S2, Guan Q1, Priest VL1
1Double Helix Consulting, Asia-Pacific, Singapore, Singapore, 2Double Helix Consulting, London,
UK
OBJECTIVES: Due to high unmet needs and low prevalence, orphan drugs can be
approved by regulatory authorities based on evidence demonstrated through sin-
gle-arm study designs; indeed, randomized studies in rare diseases may not be
feasible. As part of a health technology assessment (HTA) evidence package, how-
ever, value demonstration through comparison to existing therapies or supportive
care is always required. This study aimed to explore the value perceived by reim-
bursement authorities for an orphan therapy in a single-arm trial evidence pack-
age, and to understand any supplementary evidence requirements for value
demonstration. METHODS: Fourteen experts in HTA, pricing and reimbursement
(P&R) decison makers, and influencers in China, South Korea, Taiwan, and Thai-
land were recruited and interviewed, following a comprehensive discussion guide.
The responses were further analysed to identify the key challenges in value dem-
onstration and what clinical and economic evidence the respondents found ac-
ceptable in evaluating orphan drugs. RESULTS: In all countries, payers valued in-
novative therapies for rare diseases and were understanding towards limitations
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in study design and the availability of evidence for value demonstration. System-
atic reviews and retrospective database studies investigating the efficacy and
safety of existing therapies or supportive care, which allow for qualitative compar-
isons against the new therapy, were generally expected by most of the respon-
dents. Cost-effectiveness analysis was required in some of the countries, with the
rest expecting only a budget-impact analysis based on local epidemiological data.
Findings were similar for therapies for diseases with low prevalence but without
orphan drug designation. CONCLUSIONS: Unmet needs in rare diseases are high,
and effective new therapies are welcomed and valued by payers in these key reim-
bursed markets in Asia. Decision makers are willing to show a degree of flexibility
in their evidence requirements for these kinds of products.
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PHARMACEUTICAL BENEFIT ADVISORY COMMITTEE ACCEPTABILITY
THRESHOLD RESULTS 2005-2011
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OBJECTIVES: To examine the indicators of success in reimbursement application
in Australia made by the Pharmaceutical Benefit Advisory Committee (PBAC), and
describe the rationale behind it. Of interest is whether or not listing on the Phar-
maceutical Benefit Scheme (PBS) is recommended based on the clinical evidence,
the cost-effectiveness outcomes, political will, and whether there is clarity in the
recommendations made for the subsidisation of drugs on the PBS. This examina-
tion is conducted in order to shed light on the basis of decision making and the
impact of economic evaluations.METHODS: Themethod used in this analysis was
to differentiate the medicines into those that have never been subsidised, those
that are currently subsidised and those seeking listing of a new indication. Subse-
quently the rationales for a positive or negative recommendation for a PBS listing
are reviewed and assessed using Public Summary Documents (PSD’s). A the least
squares linear regression analysis was undertaken in order to determine which
variable impacted significantly on the PBAC’s recommendation. RESULTS: In 2007,
following 1 years worth of PSD’s, the recommendations made by the PBAC were
analysed and presented at the European iHEA. Five years later this paper presents
a follow-up to that initial research and explores the recommendationsmade by the
PBAC and the incremental cost-effectiveness ratios (ICER)which have factored into
the reimbursement recommendations. Changes in the thresholds are explored and
discussed. CONCLUSIONS: The PSD documents are now providing researchers
with an opportunity to appreciate the decision making process and what influ-
ences bare upon a key decision maker, the PBAC. It sets an example of explicit
decision making. The question that remains, however, is how transparent are the
rules and whether the outcomes confirm the perceived league table.
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SIMILAR HTA, DIFFERENT ACCESS OUTCOME? COMPARISON OF ORPHAN
ONCOLOGY DRUG ASSESSMENT IN SOUTH KOREA, AUSTRALIA AND THE UK
Saraf S, Akpinar P
PriceSpective Ltd., London, UK
OBJECTIVES: In general, demonstrating cost-effectiveness for orphan drugs in-
cluding orphan oncology agents is challenging. Reasons include high incremental
cost per QALY and insufficient clinical evidence. Even in an established Health
Technology Assessment (HTA) system such as the UK, orphan oncology agents are
often rejected as they are not cost-effective. In Asia-Pacific, South Korea and Aus-
tralia employ a similar HTA system.HTA recommendations between the countries,
however, are not always comparable. This research aims to understand the drivers
for positive recommendations and implications for improved patient access to
oncology treatments. METHODS: Review HTA recommendations in UK, Australia
and South Korea for sunitinib, dasatinib, lenalidomide, imatinib and rituximab.
Compare and contrast prices, level of clinical evidence and reimbursed patient
populations in the context of the specific assessment criteria in each country.
Identify drivers for positive recommendations. RESULTS: Of the selected drugs,
more have received positive recommendations in South Korea and Australia than
UK. A drug that receives a positive recommendation is usually priced lower in
South Korea thanAustralia or the UK. BetweenAustralia andUK, Australia tends to
reimburse at a lower price. The level of clinical evidence has less impact on eval-
uations in South Korea. In the UK, if NICE recommends an orphan oncology drug,
usually a patient access scheme is included. CONCLUSIONS: While pricing is not
dictated by NICE in the UK, access remains highly regulated. Manufacturers often
need to set up patient access schemes in order to prove their orphan oncology
drugs cost-effective and optimize patient access. On the other hand, in South Ko-
rea, the HTA process is less defined and more driven by minimizing costs. While
cost-effectiveness is the main driver for a positive recommendation, formal price
negotiation processes in South Korea and Australia lead to access more consis-
tently.
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REVIEW OF RESEARCH GUIDELINES FOR ECONOMIC EVALUATION PROPOSED
BY THE GOVERNMENT AND GOVERNMENT-FUNDED RESEARCH GROUPS IN
JAPAN
Ikeda S
International University of Health and Welfare, Ohtawara-city, Tochigi, Japan
OBJECTIVES: In Japan, introduction of economic evaluation of health policy issues
such as pricing and reimbursement of drugs and medical devices is gaining atten-
tion; several research guidelines have been proposed for the same. We compared
the key features of these guidelines and obtained suggestions for future research.
METHODS: We reviewed literature using the Ichushi database (Japanese medical
literature database) and the database on government-funded research reports, and
also contacted investigators and experts for related information. RESULTS: Four
guidelines were identified: Shiragami (2004) and Kamae (2007) groups, funded by
theMinistry of Health andWelfare, Japan, proposed two guidelines on pharmaceu-
tical pricing. The task force of the Ministry of Economy, Trade and Industry, Japan
(2007) proposed one guideline on medical device policy. The Hirota group (2011),
funded by the Ministry of Health and Welfare, Japan, proposed one guideline on
vaccination strategy. Although the headings and structures of all guidelines were
almost similar, significant differences were identified among them. For example,
two guidelines recommended societal perspective, while the other two recom-
mended consumer’s perspective. In terms of outcomemeasures, QALYs were pre-
ferred in three guidelines, whereas one recommended “the proportions of patients
who achieved target clinical results within 2 years.” Trial use was not conducted to
verify the feasibility of guidelines, except for the Hirota guideline for vaccination
policy. In addition, some recommendations had a serious problem in terms of
scientific rationality. CONCLUSIONS: There are significant variations in the key
features among all four abovementioned guidelines, and even between the two
sets of guidelines for pharmaceutical pricing decisions. To use an economic eval-
uation to aid rational resource allocation, official guidelines should be established
with scientific rigor and integrity, and future discussions about feasibility are
needed among various representatives from government, academia and industry.
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OBJECTIVES: To evaluate a Multidisciplinary Perspectives Intervention with Com-
munity Involvement (MPI&CI) which was implemented to reduce antibiotics sales
in village groceries which were illegal based on Thai Drug Act (1967). METHODS:
MPI&CI was developed based on information obtained from focus groups that in-
cluded multidisciplinary stakeholders. The intervention consisted of 1) communi-
cation about antibiotic knowledge; 2) investigation of availability of antibiotics in
groceries; and 3) informing grocery owners when antibiotics were found for sale in
their groceries. Community leaders in the intervention group were trained in a
one-dayworkshop to implementMPI&CI in their villages. A quasi-experimentwith
pretest posttest measurement was conducted to assess the effect of MPI&CI. Data
were collected from 20 villages in one district in Mahasarakham Province (inter-
vention group), and in another 20 villages in a different district in the same prov-
ince (comparison group). A generalized linear mixed model poisson regression
with repeated measures was used to evaluate the effectiveness of MPI&CI.
RESULTS: The results indicated that the intervention was effective at reducing the
number of antibiotics available for sale in groceries. Groceries in the intervention
group had 87% fewer antibiotics available at post-intervention compared with pre-
intervention (relative rate 0.13, 95% CI 0.07, 0.23), while the control group had only
an 8% reduction in antibiotic availability (relative rate 0.92, 95% CI 0.88, 0.97) be-
tween the two time periods. CONCLUSIONS: This study suggested that community
involvement during development and implementation of the intervention is an
effective approach for reducing antibiotics sales in village groceries in Thailand.
Further study should be developed to assess the sustainability and long-term ef-
fectiveness of MPI&CI.
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FACTORS INFLUENCING INTERPROFESSIONAL COLLABORATION: A
LITERATURE REVIEW FROM 2004-2011
Chang EH, Doucette WR
University of Iowa, Iowa City, IA, USA
OBJECTIVES: Interprofessional collaboration and team-based care have been re-
garded as important approaches to improve health care. Factors enhancing and
prohibiting interprofessional collaboration in practice settings, however, are not
fully understood. This study provides an updated literature review on factors in-
fluencing interprofessional collaboration from 2004-2011. METHODS: Databases
including ABI/INFORM Global, CINAHL Plus, MEDLINE, PsycINFO, Sociological Ab-
stracts, and ProQuest Dissertations & Theses were searched using keywords such
as collaboration, team, interprofessional, interdisciplinary, determinant, and fac-
tor; and subject headings such as interprofessional relations (MeSH) and multidis-
ciplinary care team (CINAHL). Only empirical studies conducted in patient care
settings examining interprofessional collaboration were retained. Due to the large
number of hits, article titles were screened prior to abstract screening and retrieval
of full articles. Salient systematic, organizational, and interactional factors identi-
fied from the articles were summarized respectively. RESULTS: Over 7000 article
titles were screened, 680 abstracts were retrieved, and 110 articles were retained. A
wide range of qualitative (N66), quantitative (N34), and mixed methods (N10)
were used in these studies. The main systematic factors included regulatory and
economic incentives, as well as professional culture differences and dominance of
medical power. Organizational factors included leadership, physical space, staff-
ing, and team training. Interactional factors, which have been studied the most
extensively, included communication, team climate, shared purpose, awareness
and respect. Additional factors included complexity of patient cases and team
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